Your Yourlocation: Home > Evaluation of tiotropium bromide(136310-93-5) in COPD patients and quality of life

COPD patients with airway obstruction often accompanied by excessive expansion of the lung, static lung volume increased. In contrast to FEV1, dyspnea is associated more closely with pulmonary hyperinflation; in contrast, effective bronchodilation and dyspnea are associated with reduced lung capacity. An important parameter that reflects COPD lung volume parameters is the deep inspiratory capacity (IC), a decrease that reflects a reduction in lung expansion. Celli et al test showed that tiotropium bromide(136310-93-5) group significantly reduced functional residual capacity, IC a corresponding increase in lung expansion to reduce the static changes in lung capacity to improve breathing difficulties.

The improvement in symptoms of COPD in patients treated with tiotropium bromide(136310-93-5) was evaluated primarily by the Mahler-converted breath-index. This is a questionnaire survey, through the patient's subjective feelings of shortness of breath scoring, score range of -9 (worst) ~ +9 (best). A change of 1 unit was considered clinically significant. The short-term dyspnea index (TDI) was measured in the long-term studies mentioned above. The results showed that the improvement of TDI in tiotropium group was better than that in control group, and there was an increasing tendency of continuous use. In a study that included salmeterol, tiotropium improved TDI better than salmeterol (P <0.05), but in other studies, the difference was not statistically significant. COPD other symptoms such as wheezing, shortness of breath, cough and chest tightness with the severity index (0 ~ 3), compared with the control group, tiotropium bromide(136310-93-5) group improved significantly wheezing and shortness of breath (P <0.05), but cough and chest tightness There was no significant difference.

The quality of life of tiotropium bromide(136310-93-5) is usually assessed by SGRQ. The questionnaire used 0 to 100 score range, the lower the score, the better the state of health, the difference of more than 4 points is considered clinically significant. The SGRQ score improved significantly with tiotropium administration compared with the control or baseline values, and the proportion of patients achieving clinical significance was also higher than that of the control group. Okudan et al. Tested the effects of tiotropium on exercise tolerance in moderate to severe stable COPD patients. There was no significant difference in the 6-min walking distance between the two groups (P> 0.05). In the treatment group, the tiotropium group (18.9 μg /ml) (P <0.05).

Address: TEL:0531-82375879 Tiotropium Bromide
© Copyright(C)2014 JINAN DEXINJIA BIO & TECH CO., LTD All Rights Reserved